BioMarin’s gene therapy reduces bleeding in hemophilia patients, making Roche look over its shoulder – STAT
STAT |
BioMarin's gene therapy reduces bleeding in hemophilia patients, making Roche look over its shoulder
STAT ATLANTA — Hemophilia researchers representing Roche (RHBBY 1) and BioMarin Pharmaceuticals (BMRN 2) shared a dais Saturday during a media briefing at the American Society of Hematology (ASH) annual meeting. That's fitting because both companies are … |
